Sarah Finocchario-Kessler1, Brad Gautney2, AnLin Cheng3, Catherine Wexler4, May Maloba5, Niaman Nazir6, Samoel Khamadi7, Raphael Lwembe7, Melinda Brown4, Thomas A Odeny8, Jacinda K Dariotis9, Matthew Sandbulte4, Natabhona Mabachi4, Kathy Goggin10. 1. Department of Family Medicine, University of Kansas Medical Center, Kansas City, KS, USA. Electronic address: skessler2@kumc.edu. 2. Global Health Innovations, Dallas, TX, USA. 3. University of Missouri-Kansas City, School of Medicine, Kansas City, MO, USA. 4. Department of Family Medicine, University of Kansas Medical Center, Kansas City, KS, USA. 5. Global Health Innovations, Nairobi, Kenya. 6. Department of Preventive Medicine, University of Kansas Medical Center, Kansas City, KS, USA. 7. Center for Virus Research, Kenya Medical Research Institute, Nairobi, Kenya. 8. University of Missouri-Kansas City, School of Medicine, Kansas City, MO, USA; Center for Microbiology Research, Kenya Medical Research Institute, Nairobi, Kenya. 9. College of Education, Criminal Justice, and Human Services, University of Cincinatti, Cincinatti, OH, USA. 10. University of Missouri-Kansas City, School of Medicine, Kansas City, MO, USA; Children's Mercy Kansas City, Health Services and Outcomes Research, Kansas City, MO, USA.
Abstract
BACKGROUND: The HIV Infant Tracking System (HITSystem) is a web-based intervention linking providers of early infant diagnosis, laboratory technicians, and mothers and infants to improve outcomes for HIV-exposed infants. We aimed to evaluate the efficacy of the HITSystem on key outcomes of early infant diagnosis. METHODS: We did a cluster-randomised trial at six hospitals in Kenya, which were matched on geographic region, resource level, and volume of patients (high, medium, and low). We randomly allocated hospitals within a matched pair to either the HITSystem (intervention; n=3) or standard of care (control; n=3). A random number generator was used to assign clusters. Investigators were unaware of the randomisation process. Eligible participants were mothers aged 18 years or older with an infant younger than 24 weeks presenting for their first early infant diagnosis appointment. The primary outcome was complete early infant diagnosis retention, which was defined as receipt of all indicated age-specific interventions until 18 months post partum (for HIV-negative infants) or antiretroviral therapy initiation (for HIV-positive infants). Analysis was per protocol in all randomised pairs judged eligible, excluding infant deaths and those who moved or were transferred to another health facility. Modified intention-to-treat sensitivity analyses judged all infant deaths and transfers as incomplete early infant diagnosis retention. Separate multivariable logistic regression analyses were done with intervention group, hospital volume, and significant covariates as fixed effects. This trial is registered with ClinicalTrials.gov, number NCT02072603; the trial has been completed. FINDINGS:Between Feb 16, 2014, and Dec 31, 2015, 895 mother-infant pairs were enrolled. Of these, 87 were judged ineligible for analysis, 26 infants died, and 92 pairs moved or were transferred to another health facility. Thus, data from 690 mother-infant pairs were analysed, of whom 392 were allocated to the HITSystem and 298 to standard of care. Mother-infant pairs were followed up to Sept 30, 2017. Infants diagnosed as HIV-positive were followed up for a median of 2·1 months (IQR 1·6-4·8) and HIV-negative infants were followed up for a median of 17·0 months (IQR 16·6-17·6). Infants enrolled in the HITSystem were significantly more likely to receive complete early infant diagnosis services compared with those assigned standard of care (334 of 392 [85%] vs 180 of 298 [60%]; adjusted odds ratio [OR] 3·7, 95% CI 2·5-5·5; p<0·0001). No intervention effect was recorded at high-volume hospitals, but strong effects were seen at medium-volume and low-volume hospitals. Modified intention-to-treat analyses for complete early infant diagnosis were also significant (334 of 474 [70%] vs 180 of 334 [54%]; adjusted OR 2·0, 95% CI 1·4-2·7; p<0·0001). No adverse events related to study participation were reported. INTERPRETATION: The HITSystem intervention is effective and feasible to implement in low-resource settings. The HITSystem algorithms have been modified to include HIV testing at birth, and an adapted HITSystem 2.0 version is supporting HIV-positive pregnant women to prevent perinatal transmission and optimise maternal and infant outcomes. FUNDING: National Institute of Child Health and Human Development.
RCT Entities:
BACKGROUND: The HIV Infant Tracking System (HITSystem) is a web-based intervention linking providers of early infant diagnosis, laboratory technicians, and mothers and infants to improve outcomes for HIV-exposed infants. We aimed to evaluate the efficacy of the HITSystem on key outcomes of early infant diagnosis. METHODS: We did a cluster-randomised trial at six hospitals in Kenya, which were matched on geographic region, resource level, and volume of patients (high, medium, and low). We randomly allocated hospitals within a matched pair to either the HITSystem (intervention; n=3) or standard of care (control; n=3). A random number generator was used to assign clusters. Investigators were unaware of the randomisation process. Eligible participants were mothers aged 18 years or older with an infant younger than 24 weeks presenting for their first early infant diagnosis appointment. The primary outcome was complete early infant diagnosis retention, which was defined as receipt of all indicated age-specific interventions until 18 months post partum (for HIV-negative infants) or antiretroviral therapy initiation (for HIV-positive infants). Analysis was per protocol in all randomised pairs judged eligible, excluding infantdeaths and those who moved or were transferred to another health facility. Modified intention-to-treat sensitivity analyses judged all infantdeaths and transfers as incomplete early infant diagnosis retention. Separate multivariable logistic regression analyses were done with intervention group, hospital volume, and significant covariates as fixed effects. This trial is registered with ClinicalTrials.gov, number NCT02072603; the trial has been completed. FINDINGS: Between Feb 16, 2014, and Dec 31, 2015, 895 mother-infant pairs were enrolled. Of these, 87 were judged ineligible for analysis, 26 infants died, and 92 pairs moved or were transferred to another health facility. Thus, data from 690 mother-infant pairs were analysed, of whom 392 were allocated to the HITSystem and 298 to standard of care. Mother-infant pairs were followed up to Sept 30, 2017. Infants diagnosed as HIV-positive were followed up for a median of 2·1 months (IQR 1·6-4·8) and HIV-negative infants were followed up for a median of 17·0 months (IQR 16·6-17·6). Infants enrolled in the HITSystem were significantly more likely to receive complete early infant diagnosis services compared with those assigned standard of care (334 of 392 [85%] vs 180 of 298 [60%]; adjusted odds ratio [OR] 3·7, 95% CI 2·5-5·5; p<0·0001). No intervention effect was recorded at high-volume hospitals, but strong effects were seen at medium-volume and low-volume hospitals. Modified intention-to-treat analyses for complete early infant diagnosis were also significant (334 of 474 [70%] vs 180 of 334 [54%]; adjusted OR 2·0, 95% CI 1·4-2·7; p<0·0001). No adverse events related to study participation were reported. INTERPRETATION: The HITSystem intervention is effective and feasible to implement in low-resource settings. The HITSystem algorithms have been modified to include HIV testing at birth, and an adapted HITSystem 2.0 version is supporting HIV-positive pregnant women to prevent perinatal transmission and optimise maternal and infant outcomes. FUNDING: National Institute of Child Health and Human Development.
Authors: Richard T Lester; Paul Ritvo; Edward J Mills; Antony Kariri; Sarah Karanja; Michael H Chung; William Jack; James Habyarimana; Mohsen Sadatsafavi; Mehdi Najafzadeh; Carlo A Marra; Benson Estambale; Elizabeth Ngugi; T Blake Ball; Lehana Thabane; Lawrence J Gelmon; Joshua Kimani; Marta Ackers; Francis A Plummer Journal: Lancet Date: 2010-11-09 Impact factor: 79.321
Authors: Phil Seidenberg; Stephen Nicholson; Merrick Schaefer; Katherine Semrau; Maximillian Bweupe; Noel Masese; Rachael Bonawitz; Lastone Chitembo; Caitlin Goggin; Donald M Thea Journal: Bull World Health Organ Date: 2012-05-01 Impact factor: 9.408
Authors: Avy Violari; Mark F Cotton; Diana M Gibb; Abdel G Babiker; Jan Steyn; Shabir A Madhi; Patrick Jean-Philippe; James A McIntyre Journal: N Engl J Med Date: 2008-11-20 Impact factor: 91.245
Authors: Sydney A Spangler; Maricianah Onono; Elizabeth A Bukusi; Craig R Cohen; Janet M Turan Journal: J Acquir Immune Defic Syndr Date: 2014-12-01 Impact factor: 3.731
Authors: Kathy Goggin; Catherine Wexler; Niaman Nazir; Vincent S Staggs; Brad Gautney; Vincent Okoth; Samoel A Khamadi; Andrea Ruff; Michael Sweat; An-Lin Cheng; Sarah Finocchario-Kessler Journal: AIDS Behav Date: 2016-09
Authors: Kathy Goggin; Emily A Hurley; Vincent S Staggs; Catherine Wexler; Niaman Nazir; Brad Gautney; Samoel A Khamadi; May Maloba; Raphael Lwembe; Sarah Finocchario-Kessler Journal: AIDS Patient Care STDS Date: 2019-08 Impact factor: 5.078
Authors: Babasola Okusanya; Linda J Kimaru; Namoonga Mantina; Lynn B Gerald; Sydney Pettygrove; Douglas Taren; John Ehiri Journal: PLoS One Date: 2022-02-25 Impact factor: 3.240
Authors: Nicole C McCann; Jennifer Cohn; Clare Flanagan; Emma Sacks; Sushant Mukherjee; Rochelle P Walensky; Oluwarantimi Adetunji; Kenneth K Maeka; Christopher Panella; Addmore Chadambuka; Haurovi Mafaune; Collins Odhiambo; Kenneth A Freedberg; Andrea L Ciaranello Journal: J Acquir Immune Defic Syndr Date: 2020-07-01 Impact factor: 3.771